Zoetis Investors Face July Deadline in Securities Fraud Lawsuit

The lawsuit, City of Ann Arbor Retiree Health Care Benefit Plan & Trust v. Zoetis Inc., claims the animal health giant failed to disclose critical weaknesses in its core portfolio. Plaintiffs allege that prescription growth for the canine pain treatment Librela stalled following FDA warnings about neurological side effects. Furthermore, the complaint asserts that key products—including Simparica Trio, Apoquel, and Cytopoint—faced significant market share erosion due to lower-priced competition.

The regulatory scrutiny and competitive pressures culminated on May 7, 2026, when Zoetis released first-quarter financial results. The report triggered a 21.5% decline in the company’s stock price. Kessler Topaz Meltzer & Check, LLP is currently advising affected shareholders on their legal options. Investors may contact attorney Jonathan Naji to discuss the potential for recovery, though they are not required to take action to remain part of the class.